IL17A and Parkinson disease: Last but not least, no studies found correlations between Th17/IL-17 and clinically relevant measures of disease state and/or progression, such as disease duration, disability scores, intensity of dopaminergic substitution therapy, etc. Clinical evidence regarding dysregulated frequency and/or function of Th17 cells in PD patients remains therefore scarce and inconclusive.